Direct percutaneous transaxillary implantation of a novel self-expandable transcatheter heart valve for aortic stenosis
Standard
Direct percutaneous transaxillary implantation of a novel self-expandable transcatheter heart valve for aortic stenosis. / Deuschl, Florian; Schofer, Niklas; Seiffert, Moritz; Hakmi, Samer; Mizote, Isamu; Schaefer, Andreas; Schirmer, Johannes; Reichenspurner, Hermann; Blankenberg, Stefan; Conradi, Lenard; Schäfer, Ulrich.
in: CATHETER CARDIO INTE, Jahrgang 90, Nr. 7, 01.12.2017, S. 1167-1174.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Direct percutaneous transaxillary implantation of a novel self-expandable transcatheter heart valve for aortic stenosis
AU - Deuschl, Florian
AU - Schofer, Niklas
AU - Seiffert, Moritz
AU - Hakmi, Samer
AU - Mizote, Isamu
AU - Schaefer, Andreas
AU - Schirmer, Johannes
AU - Reichenspurner, Hermann
AU - Blankenberg, Stefan
AU - Conradi, Lenard
AU - Schäfer, Ulrich
N1 - © 2017 Wiley Periodicals, Inc.
PY - 2017/12/1
Y1 - 2017/12/1
N2 - OBJECTIVES: The aim of this study was to evaluate safety, feasibility, and efficacy of transaxillary TAVI using a novel self-expandable transcatheter heart valve (THV) via a direct percutaneous technique.METHODS: The analysis comprises 12 consecutive patients with severe aortic stenosis treated with the ACURATE Neo™ THV (Symetis) by direct percutaneous transaxillary access.RESULTS: Patients presented with a mean age of 79.9 ± 6.2 years and high calculated surgical risk (logEuroSCORE I: 19.55 ± 15.00%; STS PROM score: 5.42 ± 3.25%). Transaxillary TAVI was performed in 11/12 via the left and in 1/12 via the right-sided axillary artery. Device success was achieved in all patients (12/12). Mortality rate at 30 days was 0% (0/12). No major and one minor access site complication (1/12) occurred. No major or life-threatening access site-related bleeding resulted. None of the patients suffered from postprocedural stroke/transient ischemic attack. There was no need for a permanent pacemaker. Mean effective orifice area post implantation was 2.1 ± 0.29 cm2 and mean aortic gradient 6.2 ± 1.5 mm Hg. In none of the patients, greater than moderate aortic regurgitation or paravalvular leakage was detected at discharge (0/12).CONCLUSIONS: Our study suggests that the implantation of the second-generation self-expandable ACURATE Neo™ via a transaxillary access is technically feasible and safe and yields excellent short-term clinical results. © 2017 Wiley Periodicals, Inc.
AB - OBJECTIVES: The aim of this study was to evaluate safety, feasibility, and efficacy of transaxillary TAVI using a novel self-expandable transcatheter heart valve (THV) via a direct percutaneous technique.METHODS: The analysis comprises 12 consecutive patients with severe aortic stenosis treated with the ACURATE Neo™ THV (Symetis) by direct percutaneous transaxillary access.RESULTS: Patients presented with a mean age of 79.9 ± 6.2 years and high calculated surgical risk (logEuroSCORE I: 19.55 ± 15.00%; STS PROM score: 5.42 ± 3.25%). Transaxillary TAVI was performed in 11/12 via the left and in 1/12 via the right-sided axillary artery. Device success was achieved in all patients (12/12). Mortality rate at 30 days was 0% (0/12). No major and one minor access site complication (1/12) occurred. No major or life-threatening access site-related bleeding resulted. None of the patients suffered from postprocedural stroke/transient ischemic attack. There was no need for a permanent pacemaker. Mean effective orifice area post implantation was 2.1 ± 0.29 cm2 and mean aortic gradient 6.2 ± 1.5 mm Hg. In none of the patients, greater than moderate aortic regurgitation or paravalvular leakage was detected at discharge (0/12).CONCLUSIONS: Our study suggests that the implantation of the second-generation self-expandable ACURATE Neo™ via a transaxillary access is technically feasible and safe and yields excellent short-term clinical results. © 2017 Wiley Periodicals, Inc.
KW - Aged
KW - Aged, 80 and over
KW - Aortic Valve Insufficiency/etiology
KW - Aortic Valve Stenosis/diagnostic imaging
KW - Axillary Artery/diagnostic imaging
KW - Catheterization, Peripheral/adverse effects
KW - Computed Tomography Angiography
KW - Coronary Angiography/methods
KW - Databases, Factual
KW - Echocardiography, Transesophageal
KW - Feasibility Studies
KW - Female
KW - Heart Valve Prosthesis
KW - Humans
KW - Male
KW - Multidetector Computed Tomography
KW - Prosthesis Design
KW - Prosthesis Failure
KW - Punctures
KW - Retrospective Studies
KW - Severity of Illness Index
KW - Time Factors
KW - Transcatheter Aortic Valve Replacement/adverse effects
KW - Treatment Outcome
U2 - 10.1002/ccd.26986
DO - 10.1002/ccd.26986
M3 - SCORING: Journal article
C2 - 28296065
VL - 90
SP - 1167
EP - 1174
JO - CATHETER CARDIO INTE
JF - CATHETER CARDIO INTE
SN - 1522-1946
IS - 7
ER -